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The co-ordinate sequencing of the human neuronal and neuroendocrine marker protein PGP 9.5 and its 
cDNA is described. The cDNA encodes the complete protein (212 amino acids), and the 340 nucleotide 
3’-noncoding region including the polyadenylation signal, indicating an mRNA slightly larger than 1 kb 
in size. Protein sequencing of 50% of PGP 9.5 confirms the deduced protein sequence. 
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Protein gene product (PGP) 9.5 is a novel 
neurone-specific protein originally discovered by 
high-resolution two-dimensional mapping of solu- 
ble proteins from different human organs [I ,2]. 
Immunohistochemistry has shown that PGP 9.5 is 
widely distributed in central and peripheral 
neurones [3], in the retina f4], and in cells of the 
diffuse neuroendocrine system (DNES) [4]. This 
distribution closely parallels that of neurone- 
specific enolase (NSE), which is the only other 
general cytoplasmic marker known for these cell 
types [5], The structure, properti~, and evolu- 
tionary distribution of PGP 9.5 have recently been 
reviewed [6]. 
To date we have been concerned with the detec- 
tion of human PGP 9.5 as a disease marker using 
poly&lon~ (e.g. 171) and monoclonal [6,8] an- 
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tibodies: here we describe the co-ordinate 
~hara~terjzation f human PGP 9.5 and its cDNA 
to provide an additional probe in the analysis of 
the developmental and functional biology and 
pathology of neurones and neuroendocrine cells. 
2, MAT~RrALS AND METHODS 
Trypsin and ch~otrypsin were from Wor- 
thington, acetonitrile from Rathburn Chemicals, 
dabsylisothiocyanate from Fluka, [T-~‘P]ATP and 
[ar-32PfdCTP from Amersham, nitroeellulose from 
Schleicher and Schuell. Other reagents and en- 
zymes were from Sigma, Boehringer, M~nheim 
and New England Biolabs. 
2.1. Analysis of pure human PGP 9.5 protein 
N-terminal analysis, and a variety of digestions 
analysed by manual and automated gas-phase se- 
quential analysis were performed. Briefly the most 
useful cleavages and resolutions of digests ob- 
tained were: (i) partial cyanogen bromide cleavage 
of unreduced PGP 9.5, then direct sequencing; (ii) 
tryptic digestion (1: 10, w/w; 3 h at 37°C; 0.1% 
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ammonium bicarbonate) of performic acid oxid- 
ized PGP 9.5 followed by 3 MM paper elec- 
trophoresis (pyridineiacetic acid/water, 100: 4 : 
900, v/v) and then perpendicular chromatography 
(isoamyl alcohol/pyridine/water, 7 : 7 : 6, v/v) with 
detection by partial fluorescamine staining; (iii) 
chymotryptic digestion (conditions as (ii)) of fully 
carboxymethylated PGP 9.5 and then resolution 
by water/acetonitrile gradient from a reverse- 
phase (PLRPS300 A, Polymer Laboratories, 
England) HPLC column using detection at 
220 nm. 
Amino acids released from the C-terminus of 
PGP 9.5 by carboxypeptidase A were identified as 
their dabsylisothiocyanate derivatives [9]. 
2.2. Oligodeoxynucleotide probe synthesis and 
screening of a cDNA library 
A ‘best guess’ 35mer, 5’-GATGGC CGGAT 
CCATTC CCTGTGAAC CATGGCGC-3 ’ , for 
the sequence DGRMPFPVNHGA was synthesized 
automatically, purified by electrophoresis and 
5 ‘-end labelled [lo]. 2 x lo5 plaques of a human 
retinal cDNA library constructed in Xgt 10 [l l] 
were screened [lo] at a stringency corresponding to 
70% probe match [12] and rescreened at higher 
temperatures. The two best positives were further 
characterized, one of which provided a fully 
deduced protein sequence. 
2.3. Analysis of cDNA clones 
Amplification, restriction mapping, subcloning 
into mp8 and sequencing by dideoxy chain ter- 
mination were performed by standard methods 
[10,13]. Homology searches both at protein and 
DNA level employed the EMBL, Genbank and 
Doolittle databases and searching programmes 
currently implemented through the Cambridge 
University Computer Network. 
3. RESULTS 
3.1. Analysis of the protein PGP 9.5 
The amino acid content [6] is very similar to that 
predicted from the cDNA sequence. The N- 
terminus appeared to be blocked, and only alanine 
could be released from the C-terminus by carbox- 
ypeptidase A. CNBr treatment gave one 
favourable cleavage releasing a 5 kDa C-terminal 
fragment with the sequence PFPV. . . . . , which 
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was subsequently encountered within both tryptic 
and chymotryptic fragments (fig. 1) and provided a 
defined site suitable for oligonucleotide probe 
deduction. A series of short and long peptides 
from tryptic and chymotryptic digests correlate 
(fig.2) with the protein sequence deduced from the 
cDNA. 
3.2. Cloning and sequencing of cDNA for 
PGP 9.5 
The labelled 35-mer produced hybridization 
signals up to 85% probe/target homology for the 
two best positive plaques. From the initial screen- 
ing, one positive (9.5 h2) provided an apparently 
full-length deduced sequence for a 23.6 kDa pro- 
tein containing all of the sequenced PGP 9.5 pep- 
tides. The analysis of this (and subsequent) cDNA 
clones was simplified by the presence of two inter- 
nal EcoRI sites which (although hindering excision 
21 -c -+ ,“r&’ 
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Fig. 1. Isolation and sequencing of peptides from PGP 
9.5 (see text for details). The numbered fragments were 
sequenced and are shown in fig.2. (A) Two-dimensional 
paper map of tryptic peptides. (B) Reverse-phase HPLC 
profile of chymotryptic peptides. The linear gradient is 
from 15% to 40% acetonitrile in water/O. 1% 
trifluoroacetic acid. 
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Fig.2. PGP 9.5 cDNA sequence and protein sequence. 
The oligonucleotide probe was derived from the region 
in brackets. Two internal EcoRI sites and a Suu3A site 
used to establish overlapping subclones for DNA 
sequencing on both strands are indicated. The Kozak 
initiation consensus, stop codon and polyadenylation 
signal (see text) are boxed. The deduced protein 
sequence is underlined for peptides which have been 
isolated and sequenced from the protein itself (see fig. 1): 
also indicated are a paper purified chymotryptic peptide 
(CTl), the C-terminal analysis (CPA), and a cyanogen 
bromide fragment (CNBr), see text. 
of the intact cDNA from the Xgt 10 EcoRI inser- 
tion site) enabled systematic sequencing of the 
three EcoRI fragments on both strands in mp8. 
Clone 9.5 h2 did not contain a polyadenylation 
signal, but rescreening of the cDNA library at high 
stringency using the internal EcoRI fragment of 
9.5 h2 as the probe identified 10 positives out of 
lo5 plaques, each containing the same EcoRI sites 
and this internal EcoRI fragment. One with a 
somewhat longer 3 ‘-representation of PGP 9.5 
mRNA encoded a 50-mer poly(A) tail preceded by 
the polyadenylation signal AATAAA and showed 
that clone 9.5 A2 extended almost to this signal. 
The cDNA clones (sequence shown in fig.2) are 
consistent with an mRNA a little larger than 1 kb 
with an abundance of about l/10000 in retinal 
poly(A)+ mRNA. No significant homologies were 
identified in the current DNA and protein 
databases. 
4. DISCUSSION 
We describe the full-length primary structure of 
human PGP 9.5 and its mRNA. The protein and 
cDNA sequences are mutually consistent. The C- 
terminus has been confirmed on three premises: 
the presence of a stop codon in the DNA sequence; 
release only of alanine from PGP 9.5 by carbox- 
ypeptidase A (which would not cleave the adjacent 
lysine); and release of a 5 kDa fragment of se- 
quence PFPV. . . . . from the intact protein by 
limited cleavage with cyanogen bromide. The N- 
terminus of PGP 9.5 appears to be blocked and 
has not been confirmed directly, but the cir- 
cumstantial data including an in-frame sequenced 
peptide starting 7 amino acids downstream, an in- 
frame stop codon 25 nucleotides upstream and 
DNA sequence at positions - 5 to - 1 fitting the 
Kozak initiation consensus [ 141 substantiate the in- 
itiation methionine of the deduced protein se- 
quence. The molecular mass of the predicted 
protein is 23.6 kDa compared with estimates of 
24-27 kDa from denaturing gel electrophoresis of 
PGP 9.5 [2]. The lack of homology with any 
previously described protein confirms the identity 
of PGP 9.5 as a new marker for neurones and cells 
of the diffuse neuroendocrine system. 
The protein is estimated to represent 0.5-l % of 
total soluble brain protein [2]: here we estimate 
that its mRNA is above 0.01% of total retinal 
159 
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mRNA, and since only a proportion of brain and 
retinaI celts contain PGP 9.5 {3,4j the neuronal 
concentration of both protein and mRNA are like- 
ly to be higher, 
The primary protein structure opens the 
possibility for more refined immuuochemica1 
studies, and the cf>NA probes provide an impor- 
tant tool in studying the developmental biology of 
PGP 8.5 as a generai c~op~asrni~ marker of 
neuranes and neuroendocrine cells, a diverse group 
of cells long noted to possess developmental 
simi~~ities [15], which may now be invest~ated at 
the molecular level. 
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